Medicines labeled for the same conditions
Alternatives to dolutegravir and rilpivirine
38 other medicines are given the same way (oral) and in the same FDA class as dolutegravir and rilpivirine or labeled mainly for the same use (HIV); 12 are in its class, human immunodeficiency virus integrase strand transfer inhibitors: etravirine, nevirapine, raltegravir, efavirenz and 8 more; the others include 9 hepatitis b virus nucleoside analog reverse transcriptase inhibitors, 6 cytochrome p450 3a inhibitors and 4 protease inhibitors (FDA labels read October 8, 2026). In the same class, the lowest pharmacy cost is $0.147 per nevirapine 200 mg tablet (what pharmacies paid in the NADAC survey; strengths differ).
Which medicines are labeled for the same conditions as dolutegravir and rilpivirine?
The first 24 of the 38, the same class first. HIV lists all 47 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (oral) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Dolutegravir and rilpivirinehuman immunodeficiency virus integrase strand transfer inhibitor | this medicine | none listed | $121.87 per tablet 50-25 mg tablet | No | No current entry |
| Etravirinehuman immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor · same class | HIV | 5 labelers | $9.94 per tablet 200 mg tablet | No | A presentation being discontinued |
| Nevirapinehuman immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor · same class | HIV | 6 labelers | $0.147 per tablet 200 mg tablet | Yes | No current entry |
| Raltegravirhuman immunodeficiency virus integrase strand transfer inhibitor · same class | HIV | 1 labeler | $34.54 per tablet 400 mg tablet | No | No current entry |
| Efavirenzhuman immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor · same class | HIV | 5 labelers | $1.28 per tablet 600 mg tablet | No | No current entry |
| Efavirenz and emtricitabine and tenofovir disoproxilhuman immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor · same class | HIV | 7 labelers | $1.12 per tablet 600-200-300 mg tablet | Yes | No current entry |
| Efavirenz and lamivudine and tenofovir disoproxilhuman immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor · same class | HIV | 1 labeler | n/a | Yes | No current entry |
| Doravirinehuman immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor · same class | HIV | none listed | $60.79 per tablet 100 mg tablet | No | No current entry |
| Cabotegravirhuman immunodeficiency virus integrase strand transfer inhibitor · same class | HIV | none listed | n/a | Yes | No current entry |
| Cobicistat, elvitegravir, emtricitabine and tenofovir alafenamidecytochrome p450 3a inhibitor · same class | HIV | none listed | $143.35 per tablet Genvoya tablet | Yes | No current entry |
| Cobicistat, elvitegravir, emtricitabine and tenofovir disoproxilcytochrome p450 3a inhibitor · same class | HIV | none listed | $150.14 per tablet Stribild tablet | Yes | No current entry |
| Doravirine and islatravirhuman immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor · same class | HIV | none listed | n/a | No | No current entry |
| Doravirine and lamivudine and tenofovir disoproxilhuman immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor · same class | HIV | none listed | $93.06 per tablet 100-300-300 mg tablet | Yes | No current entry |
| Emtricitabine and tenofovir disoproxilhepatitis b virus nucleoside analog reverse transcriptase inhibitor | HIV | 25 labelers | $0.529 per tablet 200-300 mg tablet | Yes | No current entry |
| Darunavirprotease inhibitor | HIV | 13 labelers | $1.16 per tablet 600 mg tablet | No | No current entry |
| Lamivudinehepatitis b virus nucleoside analog reverse transcriptase inhibitor | HIV | 14 labelers | $0.489 per tablet 150 mg tablet | Yes | No current entry |
| Tenofovir disoproxilhepatitis b virus nucleoside analog reverse transcriptase inhibitor | HIV | 15 labelers | $0.294 per tablet 300 mg tablet | Yes | No current entry |
| Maravirocccr5 co-receptor antagonist | HIV | 8 labelers | $9.15 per tablet 150 mg tablet | Yes | A presentation being discontinued |
| Atazanavirprotease inhibitor | HIV | 4 labelers | $2.23 per capsule 300 mg capsule | No | No current entry |
| Abacavirhuman immunodeficiency virus nucleoside analog reverse transcriptase inhibitor | HIV | 12 labelers | $0.546 per tablet 300 mg tablet | Yes | No current entry |
| Lamivudine and zidovudinehepatitis b virus nucleoside analog reverse transcriptase inhibitor | HIV | 7 labelers | $0.771 per tablet Lamivudine-zidovudine tablet | Yes | No current entry |
| Ritonavircytochrome p450 3a inhibitor | HIV | 7 labelers | $0.607 per tablet 100 mg tablet | Yes | A presentation being discontinued |
| Lopinavir and ritonavircytochrome p450 3a inhibitor | HIV | 3 labelers | $4.46 per tablet 200-50 mg tablet | No | A presentation being discontinued |
| Zidovudinehuman immunodeficiency virus nucleoside analog reverse transcriptase inhibitor | HIV | 3 labelers | $0.464 per tablet 300 mg tablet | Yes | No current entry |
| Abacavir and lamivudinehepatitis b virus nucleoside analog reverse transcriptase inhibitor | HIV | 6 labelers | $1.48 per unit 600-300 mg | Yes | No current entry |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What do pharmacies pay for each?
The headline NADAC price per unit of each medicine's most widely listed form; strengths differ, so compare like with like on each record.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What next?
- Dolutegravir and rilpivirine: the full record
- label, generics, price, shortages, recalls